Atomoxetine

Also known as: (R)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine

Active ingredient description

Atomoxetine is a highly selective and potent inhibitor of the pre-synaptic noradrenaline transporter, its presumed mechanism of action, without directly affecting the serotonin or dopamine transporters.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
N06BA09
Atomoxetine
N Nervous system → N06 Psychoanaleptics → N06B Psychostimulants, agents used for ADHD and nootropics → N06BA Centrally acting sympathomimetics
Discover more medicines within N06BA09

Medicines

Atomoxetine is the active ingredient of these drugs:

Drug
Countries
AGAKALIN

Germany

ATAMA

Hong Kong

ATAMAX

Spain

ATOFAB

Austria Poland

ATOMAID

United Kingdom

ATOMERRA

Australia

ATOMOTERA

Hong Kong

ATOMOXE

Germany

AUDALIS

Austria Netherlands

DEZAPREX

Spain

KONATEN

Poland

STRATTERA

Australia Austria Canada Cyprus Finland

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
STRATTERA Capsule, hard
Summary of product characteristics (SPC)
UK

Structural formula

Graphic representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

ASW034S0B8 - ATOMOXETINE

CAS registry number

83015-26-3 - atomoxetine

SNOMED-CT

407037005 - Atomoxetine (substance)

Next: Usage